The Role of Anti-skin Antibodies Immunoglobulin G in the Diagnosis of Autoimmune Bullous Diseases

Authors

  • Akram Deghady  Clinical and Chemical Pathology Department, Faculty of Medicine, Alexandria, Egypt
  • Khalid El Molla  Dermatology, Venereology and Andrology Department, Faculty of Medicine, Alexandria, Egypt
  • Mona Ayad  Clinical and Chemical Pathology Department, Faculty of Medicine, Alexandria, Egypt
  • Ebtesam Elsayed  Clinical and Chemical Pathology Department, Faculty of Medicine, Alexandria, Egypt

Keywords:

Autoimmune Bullous Diseases, Pemphigus Vulgaris, Anti-Skin Antibodies IgG, Indirect Immunofluorescence

Abstract

Background: Autoimmune bullous diseases (AIBDs) represent a group of acquired heterogenous organ-specific disorders in which pathogenic autoantibodies, commonly of IgG and/or IgA classes, target adhesion molecules of the skin and mucous membranes. These disorders are caused by the interaction between autoantibodies and structures essential for the integrity of the skin, either on keratinocytes cell surface or in the dermo-epidermal junction, leading to cleavage of the skin at different levels. Consequently, according to the level of cleavage, AIBDs are classified into intraepidermal and subepidermal blistering diseases. Diagnosis of AIBDs depends on the clinical, histological and immunological characteristics of each subtype. Immunofluorescence is pivotal for diagnosing AIBDs. Tissue-bound and/or circulating autoantibodies and the patterns of their binding to specific antigens can be demonstrated by direct and indirect immunofluorescence, respectively.

Aim of the Work: To evaluate the performance characteristics of anti-skin antibodies IgG by indirect immunofluorescence (IIF) in the diagnosis of autoimmune bullous diseases.

Subjects and Methods: Twenty-five patients with AIBDs including 14 pemphigus vulgaris (PV) patients, 5 pemphigus foliaceus (PF) patients and 6 bullous pemphigoid (BP) patients were studied, and compared with 10 patients with non-bullous skin diseases and 10 healthy subjects as controls. ASA-IgG were investigated by using IIF technique.

Results: Positive anti-skin antibodies (ASA)-IgG IIF test was demonstrated in 92% of AIBD patients and in 20% of patients with non-bullous skin diseases. The test was negative in all ten healthy subjects. Thus, ASA-IgG were significantly positive in AIBDs than both non-bullous diseases patients and healthy control group. Two patterns of ASA-IgG binding to the corresponding antigens were seen; intercellular substance (ICS) pattern with serum samples from PV and PF patients that diagnose intraepidermal blistering diseases. Linear basement membrane zone (BMZ) pattern by serum samples obtained from BP patients that diagnose subepidermal blistering diseases.

Conclusions: IIF assay is an accurate screening test for detection of circulating ASA-IgG that categorizes autoimmune bullous disorders into two major subtypes: pemphigus and pemphigoid based on antibody deposits staining patterns either ICS or linear BMZ pattern, respectively.

References

  1. Ishii K. Importance of serological tests in diagnosis of autoimmune blistering diseases. J Dermatol. 2015; 42(1):3-10.
  2. Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 1: Clinical manifestations. J Dtsch Dermatol Ges. 2011; 9(10):844-56.
  3. Kitajima Y. A new perspective of autoimmune bullous diseases: molecular cell biology of blistering mechanisms and logical treatments. Dermatol Sinica. 2008; 26(2):52-64.
  4. Schmidt E, Zillikens D. Pemphigoid diseases. The Lancet. 2013; 381(9863):320-32.
  5. Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 2: diagnosis and therapy. J Dtsch Dermatol Ges. 2011; 9(11):927-47.
  6. Beek NV, Knuth-Rehr D, Altmeyer P, Assaf C, et al. Diagnostics of autoimmune bullous diseases in German dermatology departments. J Dtsch Dermatol Ges. 2012; 10(7):492-9.
  7. Rastogi V, Sharma R, Misra SR, Yadav L. Diagnostic procedures for autoimmune vesiculobullous diseases: A review. J Oral Maxillofac Pathol. 2014; 18(3):390-7.
  8. Zhou T, Fang S, Li C, Hua H. Comparative study of indirect immunofluorescence, enzyme-linked immunosorbent assay, and the Tzanck smear test for the diagnosis of pemphigus. J Oral Pathol Med. 2016; 45(10):786-90.
  9. Sárdy M, Kostaki D, Varga R, Peris K, Ruzicka T. Comparative study of direct and indirect immunofluorescence and of bullous pemphigoid 180 and 230 enzyme-linked immunosorbent assays for diagnosis of bullous pemphigoid. J Am Acad Dermatol. 2013; 69(5):748-53.
  10. Harman KE, Gratian MJ, Bhogal BS, Challacombe SJ, Black MM. The use of two substrates to improve the sensitivity of indirect immunofluorescence in the diagnosis of pemphigus. Br J Dermatol. 2000; 142(6):1135-9.
  11. Marinovi? B. Comparison of diagnostic value of indirect immunofluorescence assay and desmoglein ELISA in the diagnosis of pemphigus. Acta Dermatovenerol Croat. 2010; 18(2):79-83.
  12. Wang HH, Chen YT, Chen WY, Chen TJ. The use of anti-intercellular substance antibody in diagnosing patients with clinical suspicion of pemphigus. Dermatologica Sinica. 2016, doi:10.1016/j.dsi.2016.03.007.
  13. Aksu D, Peksari Y, Arica IE, Gurgey E. Assessing the autoantibody levels in relation to disease severity and therapy response in pemphigus patients. Indian J Dermatol. 2010; 55(4):342-7.
  14. Ng PP, Thng ST, Mohamed K, Tan SH. Comparison of desmoglein ELISA and indirect immunofluorescence using two substrates (monkey oesophagus and normal human skin) in the diagnosis of pemphigus. Australas J Dermatol. 2005; 46(4):239-41.
  15. Barnadas MA, Rubiales M, González M, Puig L, García P, Baselga E, Pujol R, Alomar A, Gelpí C. Enzyme?linked immunosorbent assay (ELISA) and indirect immunofluorescence testing in a bullous pemphigoid and pemphigoid gestationis. Int J Dermatol. 2008; 47(12):1245-9.
  16. Seline AE, Lauren NS, Olayemi S, Kiran M. Comparison of histopathology, immunofluorescence, and serology for the diagnosis of autoimmune bullous disorders: an update. Glob Dermatol. 2016; 3(4):343-51.
  17. Jarz?bek-Chorzelska M, Strasz-Kolaci?ska Z, Sulej J, Jablonska S. The use of two substrates for indirect immunofluorescence in the diagnosis of pemphigus. Br J Dermatol. 2001; 145(1):178-80.
  18. Barnadas MA, Rubiales M, Gich I, Gelpí C. Usefulness of specific anti-desmoglein 1 and 3 enzyme-linked immunoassay and indirect immunofluorescence in the evaluation of pemphigus activity. Intl J Dermatol. 2015; 54(11):1261-8.
  19. Kamiya K, Aoyama Y, Shirafujo Y, et al. Detection of antibodies against the non-calcium-dependent epitopes of desmoglein 3 in pemphigus vulgaris and their pathogenic signi?cance. Br J Dermatol 2012; 167(2): 252–61.
  20. Daneshpazhooh M, Zafarmand SV, Balighi K, Hosseini SH, Ramezani A, Kalantari MS, Ghandi N, Ghiasi M, Nikoo A, Chams-Davatchi C. Immunologic prediction of relapse in patients with pemphigus vulgaris (PV) in clinical remission. J Am Acad Dermatol. 2016; 74(6):1160-5.
  21. Muro Y, Sugiura K, Akiyama M. What are the “True” Pathogenic Anti-desmoglein Antibodies?. Acta Derm venereol. 2015; 95(7):872-4.
  22. Yokouchi M, Saleh MA, Kuroda K, Hachiya T, Stanley JR, Amagai M, Ishii K. Pathogenic epitopes of autoantibodies in pemphigus reside in the amino-terminal adhesive region of desmogleins which are unmasked by proteolytic processing of prosequence. J Invest Dermatol. 2009; 129(9):2156-66.
  23. Yamagami J, Kacir S, Ishii K, Payne AS, Siegel DL, Stanley JR. Antibodies to the desmoglein 1 precursor proprotein but not to the mature cell surface protein cloned from individuals without pemphigus. J Immunol. 2009; 183(9):5615-21.
  24. Sharma PM, Choi EJ, Kuroda K, Hachiya T, Ishii K, Payne AS. Pathogenic anti-desmoglein Mabs show variable ELISA activity because of preferential binding of mature versus proprotein isoforms of desmoglein 3. J Invest Dermatol. 2009; 129(9):2309-12.
  25. Koga H, Tsuruta D, Ohyama B, et al. Desmoglien 3, its pathogenicity and a possibility for therapeutic target in pemphigus vulgaris. Expert Opin Ther Targets. 2013; 17(3):293-306.
  26. Di Zenzo G, Amber KT, Sayar BS, Müller EJ, Borradori L. Immune response in pemphigus and beyond: progresses and emerging concepts. Semin Immunopathol. 2016; 38(1):57-74.
  27. Kamiya K, Aoyama Y, Shirafuji Y, Hamada T, Morizane S, Fujii K, Iwatsuki K. A higher correlation of the antibody activities against the calcium-dependent epitopes of desmoglein 3 quantified by ethylenediaminetetraacetic acid-treated enzyme-linked immune-sorbent assay with clinical disease activities of pemphigus vulgaris. J Dermatol Sci. 2013; 70(3):190-5.
  28. Funakoshi T, Lunardon L, Ellebrecht CT, Nagler AR, O’Leary CE, Payne AS. Enrichment of total serum IgG4 in patients with pemphigus. Br J Dermatol. 2012; 167(6):1245-53.
  29. Pan M, Haiqin ZHU, Renchao XU. Immune cellular regulation on autoantibody production in pemphigus. J Dermatol. 2015; 42(1):11-7.
  30. Kwon HH, Kwon IH, Chung JH, Youn JI. Pemphigus foliaceus associated with psoriasis during the course of narrow-band UVB therapy: a simple coincidence?. Ann Dermatol. 2011; 23(Suppl 3):S281-4.
  31. Ohata C, Ishii N, Koga H, Fukuda S, Tateishi C, Tsuruta D, Furumura M, Hashimoto T. Coexistence of autoimmune bullous diseases (AIBDs) and psoriasis: A series of 145 cases. J Am Acad Dermatol. 2015; 73(1):50-5.

International Journal of Scientific Research in Science and Technology

Downloads

Published

2016-12-30

Issue

Volume 2, Issue 6 , November-December-2016

Section

Research Articles

License

Copyright (c) IJSRST

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

[1]
Akram Deghady, Khalid El Molla, Mona Ayad, Ebtesam Elsayed, " The Role of Anti-skin Antibodies Immunoglobulin G in the Diagnosis of Autoimmune Bullous Diseases, International Journal of Scientific Research in Science and Technology(IJSRST), Online ISSN : 2395-602X, Print ISSN : 2395-6011, Volume 2, Issue 6 , pp.59-65, November-December-2016.